D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 76 Citations 20,008 461 World Ranking 11879 National Ranking 401

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Surgery

Internal medicine, Ovarian cancer, Cancer research, Pathology and Cancer are her primary areas of study. Her Internal medicine research integrates issues from Gastroenterology, Endocrinology and Oncology. Her research integrates issues of Stage and Epidermal growth factor in her study of Oncology.

Her Ovarian cancer research is multidisciplinary, incorporating perspectives in Laparotomy, Class III β-tubulin and Laparoscopy. Her work deals with themes such as Radiology and Histopathology, which intersect with Cancer. Gabriella Ferrandina has researched Surgery in several fields, including Cervical cancer and Radical surgery.

Her most cited work include:

  • Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas (766 citations)
  • CLASS III BETA-TUBULIN OVEREXPRESSION IS A PROMINENT MECHANISM OF PACLITAXEL RESISTANCE IN OVARIAN CANCER PATIENTS (281 citations)
  • Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. (227 citations)

What are the main themes of her work throughout her whole career to date?

Her scientific interests lie mostly in Internal medicine, Surgery, Ovarian cancer, Oncology and Cervical cancer. Her Internal medicine research incorporates elements of Gastroenterology and Endocrinology. Her Ovarian cancer research is multidisciplinary, relying on both Cancer research, Carboplatin, Paclitaxel, Ovary and Carcinoma.

Her studies deal with areas such as Gemcitabine, Disease and Trabectedin as well as Oncology. Her Cervical cancer study also includes fields such as

  • Radical surgery that connect with fields like Concomitant and Neoadjuvant therapy,
  • Lymph node and related Surgical oncology. Her studies examine the connections between Cancer and genetics, as well as such issues in Pathology, with regards to Metastasis.

She most often published in these fields:

  • Internal medicine (51.05%)
  • Surgery (35.31%)
  • Ovarian cancer (30.42%)

What were the highlights of her more recent work (between 2015-2021)?

  • Internal medicine (51.05%)
  • Surgery (35.31%)
  • Cervical cancer (24.13%)

In recent papers she was focusing on the following fields of study:

Her primary scientific interests are in Internal medicine, Surgery, Cervical cancer, Oncology and Stage. Her work is connected to Ovarian cancer, Chemotherapy, Disease, Progression-free survival and Phases of clinical research, as a part of Internal medicine. Her Surgery study combines topics from a wide range of disciplines, such as Lymphadenectomy and Radical Hysterectomy.

Her Cervical cancer research includes elements of Lymph node, Radiology, Locally advanced, Chemoradiotherapy and Radical surgery. Her biological study deals with issues like Trabectedin, which deal with fields such as Platinum sensitive and Pegylated Liposomal Doxorubicin. As a part of the same scientific family, Gabriella Ferrandina mostly works in the field of Stage, focusing on Radiation therapy and, on occasion, Clinical trial.

Between 2015 and 2021, her most popular works were:

  • Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. (166 citations)
  • Optimizing treatment in recurrent epithelial ovarian cancer. (53 citations)
  • Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study (34 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Surgery

Her scientific interests lie mostly in Surgery, Internal medicine, Ovarian cancer, Oncology and Cervical cancer. In her research, Clear cell carcinoma, Abdominal mass, Rectus abdominis muscle, Abdominal wall and Carcinoma is intimately related to Radical Hysterectomy, which falls under the overarching field of Surgery. Her Ovarian cancer research incorporates elements of Survival rate, Invadopodia, Proportional hazards model, Cortactin and RhoC.

Her Oncology research incorporates themes from Disease and Chemotherapy. Her Cervical cancer research also works with subjects such as

  • Lymph node which is related to area like Univariate analysis, Metastasis and Surgical oncology,
  • Brachytherapy and related Urinary system, Group B and Primary tumor,
  • Chemoradiotherapy that connect with fields like Urology, Neoadjuvant therapy, Statistical significance and Pathology. The Retrospective cohort study study which covers Stage that intersects with Radiology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

A. Bellacosa;D. De Feo;A. K. Godwin;D. W. Bell.
International Journal of Cancer (1995)

1096 Citations

CLASS III BETA-TUBULIN OVEREXPRESSION IS A PROMINENT MECHANISM OF PACLITAXEL RESISTANCE IN OVARIAN CANCER PATIENTS

Simona Mozzetti;Cristiano Ferlini;Paola Concolino;Flavia Filippetti.
Clinical Cancer Research (2005)

431 Citations

Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

G. Scambia;F. O. Ranelletti;P. Benedetti Panici;R. De Vincenzo.
Cancer Chemotherapy and Pharmacology (1994)

373 Citations

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma

M Maurizi;G Almadori;G Ferrandina;M Distefano.
British Journal of Cancer (1996)

345 Citations

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo.
Lancet Oncology (2014)

303 Citations

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

Gabriella Ferrandina;Manuela Ludovisi;Domenica Lorusso;Sandro Pignata.
Journal of Clinical Oncology (2008)

301 Citations

A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.

Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Alfredo Ercoli.
Annals of Surgical Oncology (2006)

274 Citations

Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients

Gabriella Ferrandina;Gian Franco Zannoni;Enrica Martinelli;Amelia Paglia.
Clinical Cancer Research (2006)

273 Citations

Expression of CD133-1 and CD133-2 in ovarian cancer.

G. Ferrandina;G. Bonanno;L. Pierelli;A. Perillo.
International Journal of Gynecological Cancer (2008)

268 Citations

Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.

Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Giorgia Garganese.
American Journal of Obstetrics and Gynecology (2008)

257 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Gabriella Ferrandina

Giovanni Scambia

Giovanni Scambia

Catholic University of the Sacred Heart

Publications: 273

Nicoletta Colombo

Nicoletta Colombo

European Institute of Oncology

Publications: 41

Jalid Sehouli

Jalid Sehouli

Charité - University Medicine Berlin

Publications: 39

Ignace Vergote

Ignace Vergote

KU Leuven

Publications: 39

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 34

Dennis S. Chi

Dennis S. Chi

Memorial Sloan Kettering Cancer Center

Publications: 32

Anil K. Sood

Anil K. Sood

The University of Texas MD Anderson Cancer Center

Publications: 31

Claes G. Tropé

Claes G. Tropé

University of Oslo

Publications: 31

Yong Sang Song

Yong Sang Song

Seoul National University

Publications: 29

Young Tae Kim

Young Tae Kim

Seoul National University Hospital

Publications: 29

Dirk Timmerman

Dirk Timmerman

KU Leuven

Publications: 29

Robert L. Coleman

Robert L. Coleman

The University of Texas MD Anderson Cancer Center

Publications: 28

Frédéric Amant

Frédéric Amant

Antoni van Leeuwenhoek Hospital

Publications: 28

Ben Davidson

Ben Davidson

Oslo University Hospital

Publications: 26

Michael J. Birrer

Michael J. Birrer

University of Arkansas for Medical Sciences

Publications: 25

Tom Bourne

Tom Bourne

Imperial College London

Publications: 24

Trending Scientists

Franck Cappello

Franck Cappello

Argonne National Laboratory

David Saad

David Saad

Aston University

Gerald Schaefer

Gerald Schaefer

Loughborough University

Peng Gao

Peng Gao

Harbin Engineering University

Justin D. Holmes

Justin D. Holmes

University College Cork

Sven G. Nilsson

Sven G. Nilsson

Lund University

Emily H. Stanley

Emily H. Stanley

University of Wisconsin–Madison

Thomas Lecuit

Thomas Lecuit

Collège de France

Vincenzo Petrarca

Vincenzo Petrarca

Sapienza University of Rome

Ian N. Clarke

Ian N. Clarke

University of Southampton

Binyamin Hochner

Binyamin Hochner

Hebrew University of Jerusalem

Eric A. Youngstrom

Eric A. Youngstrom

University of North Carolina at Chapel Hill

John E. Mayer

John E. Mayer

Boston Children's Hospital

Raymond C. Rosen

Raymond C. Rosen

New England Research Institutes

Fray F. Marshall

Fray F. Marshall

Emory University

Luk Warlop

Luk Warlop

BI Norwegian Business School

Something went wrong. Please try again later.